Last reviewed 2026-04-20 · How we verify

Pyridylcarbinol (nicotinyl alcohol)

Pyridylcarbinol (generic name: nicotinyl alcohol) is a nicotinyl alcohol drug. It is currently in unknown development for Hyperlipidemia, Ménière's disease, Niacin deficiency.

Pyridylcarbinol works by providing the body with a precursor to NAD+, a crucial coenzyme involved in energy metabolism.

Pyridylcarbinol, also known as nicotinyl alcohol, is a small molecule drug in the nicotinyl alcohol class. It is used to treat Hyperlipidemia, Ménière's disease, Niacin deficiency, and Pellagra. However, its original developer and current owner are unknown, and its commercial status, including FDA approval and off-patent status, is also unclear. Further research is needed to understand its mechanism of action and key safety considerations. As a result, its use should be approached with caution.

At a glance

Mechanism of action

Think of it like a puzzle piece. NAD+ is a key part of how our cells make energy, and pyridylcarbinol helps fill in the gaps by providing a building block for NAD+. This can help our cells function properly and support overall health.

Approved indications

• Hyperlipidemia
• Ménière's disease
• Niacin deficiency
• Pellagra

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pyridylcarbinol CI brief — competitive landscape report
• Pyridylcarbinol updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Pyridylcarbinol

Related

• Drug class: All nicotinyl alcohol drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Metabolic
• Indication: Drugs for Hyperlipidemia
• Indication: Drugs for Ménière's disease
• Indication: Drugs for Niacin deficiency

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing